Please Wait...

MRP 8/14 // Myeloid Related Protein 8 and Myeloid Related Protein 14 (S100A8/S100A9, Calprotectin)

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Calprotectin is a heterodimer of the two calcium-binding proteins Calgranulin A (S100A8) and Calgranulin B (S100A9), also called Myeloid Related Protein (MRP) 8/MRP14. These non-covalently associated proteins constituted about 45% of the protein content of neutrophils cytosol and are 40-fold more abundant in neutrophils versus monocytes (Edgeworth et al., 1991). MRP8/14 is also present in macrophages of rheumatoid polyarthritic synovialis but not in normal tissue macrophages (Odink et al., 1987). This heterodimer belong to the alarmin family. Alarmins are released upon tissue injury and promotes inflammation.

Since MRP8/14 is locally released from damaged or inflamed tissues, it has been regarded as a biomarker. MRP8/14 has been shown to be a useful biomarker in sepsis, auto-immunes diseases, respiratory diseases, Kawasaki disease, inflammatory bowel syndrome (fecal calprotectin) and multiple sclerosis (Chan et al., 2012).

 

MRP8/14 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum.

 

Chan, J.K., Roth, J., Oppenheim, J.J., Tracey, K.J., Vogl, T., Feldmann, M., Horwood, N., and Nanchahal, J. (2012). Alarmins: awaiting a clinical response. J. Clin. Invest. 122, 2711–2719.

Edgeworth, J., Gorman, M., Bennett, R., Freemont, P., and Hogg, N. (1991). Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J. Biol. Chem. 266, 7706–7713.

Odink, K., Cerletti, N., Brüggen, J., Clerc, R.G., Tarcsay, L., Zwadlo, G., Gerhards, G., Schlegel, R., and Sorg, C. (1987). Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 330, 80–82.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @bioclinica: @CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of #MobileTechnologies in #CV…
bioclinica (5 minutes ago)
@CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of… https://t.co/0Oc3z6zkO8
bioclinica (10 minutes ago)
RT @CDISC: Special thanks to CDISC Member @bioclinica for hosting CDISC Public Training in Audubon, PA 2-6 Apr 2018. Register today. https:…
bioclinica (26 minutes ago)
Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil… https://t.co/77NOME2Dj7
bioclinica (Yesterday)
Who made the BioSpace list of 11 most innovative life sciences companies in the world? Ck it out here via @biospace… https://t.co/f9vtRpsbMW
bioclinica (Yesterday)
BREAKING: With a passion for Drug Safety, we’re delighted to share @bioclinica #pharmacovigilance crossed 1M ICSR c… https://t.co/PAdROjo7tE
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen